Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

Item
http://www.wikidata.org/entity/Q33696008
Trial Watch: Proteasomal inhibitors for anticancer therapyOutcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home.Retreatment and Prolonged Therapy with Subcutaneous Bortezomib in Patients with Relapsed Multiple Myeloma: A Randomized, Controlled, Phase III Study.An update in treatment options for multiple myeloma in nontransplant eligible patients.Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma.Early mortality in multiple myeloma: Experiences from a single institution.Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.Falls in older adults with multiple myeloma.
P2860

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

Item
http://www.wikidata.org/entity/Q33696008
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Bortezomib cumulative dose, ef ...... eligible for high-dose therapy
@ast
Bortezomib cumulative dose, ef ...... eligible for high-dose therapy
@en
type
label
Bortezomib cumulative dose, ef ...... eligible for high-dose therapy
@ast
Bortezomib cumulative dose, ef ...... eligible for high-dose therapy
@en
prefLabel
Bortezomib cumulative dose, ef ...... eligible for high-dose therapy
@ast
Bortezomib cumulative dose, ef ...... eligible for high-dose therapy
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
Bortezomib cumulative dose, ef ...... eligible for high-dose therapy
@en
P2093
P2860
P304
P31
P356
10.3324/HAEMATOL.2013.099341
P433
P478
P50
P577
P5875
P698
P932